Hydrocortisone Probutate

Summary

Hydrocortisone Probutate (CHEMBL1200953) is an approved small molecule (ATC D07AB11); indicated across 1 condition including skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D07AB11
• Indications: 1 condition
• Chemistry: 488.6 Da · C28H40O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200953
Name	Hydrocortisone Probutate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	636398
ATC	D07AB11
Molecular formula	C28H40O7
Molecular weight	488.6
InChIKey	FOGXJPFPZOHSQS-AYVLZSQQSA-N

SMILES: CCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(C[C@@H]([C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)O)C)C(=O)COC(=O)CC

IUPAC name: [(8S,9S,10R,11S,13S,14S,17R)-11-hydroxy-10,13-dimethyl-3-oxo-17-(2-propanoyloxyacetyl)-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] butanoate

Also known as: Hydrocortisone buteprate, Hydrocortisone butyrate propionate, Hydrocortisone probutat, Hydrocortisone probutate, Pandel, TS 408, TS-408, HYDROCORTISONE PROBUTATE, SID144206491

Patent coverage: 609 distinct patent families (2,182 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
skin disorder	4	MONDO:0005093	EFO:0000701

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).